Ask The Board

1. What Tips Would You Give To An Early-Stage Biopharma CEO Preparing To Present New Clinical Data At A Medical Meeting? 2/1/2023

   See the answer from Rich Daly, president at CARsgen Therapeutics.

2. Do You Think That Biopharmaceutical Companies Receiving An FDA Accelerated Approval Should Be Required To Enroll Patients In A Confirmatory Study Prior To Launch? 2/1/2023

   See the answer from Mary Rose Keller, VP of clinical operations at Acrivon Therapeutics.

3. What Key Characteristics Or Attributes — Beyond Functional Or Scientific Expertise — Should A CEO Look For In Considering The Addition Of A New Board Member? 1/3/2023

   See the answer from Thomas Wiggans, chairman and CEO of Pardes Biosciences.

4. What Advice Would You Give To Small Biotechs That Have Delayed Or Canceled Plans For A Public Offering, But Still Need Funding To Advance Clinical Programs? 1/3/2023

   See the answer from Pamela Reilly Contag Ph.D., CEO and President at BioEclipse Therapeutics.

5. What Impact Do You Think The Inflation Reduction Act Will Have On The Biopharma Industry Over The Next Five Years? 12/1/2022

   See the answer from Ron Cohen, president and CEO at Acorda Therapeutics.

6. What Factors Are Most Important To Consider When Collaborating Externally On A Combination Drug Clinical Trial? 12/1/2022

   See the answer from Martin Lehr, CEO at Context Therapeutics.

7. What Do Corporate Diversity, Equity, And Inclusion (DE&I) Programs Most Often Get Wrong? How Could They Be Improved? 11/1/2022

   See the answer from Paul Hastings, president and CEO of Nkarta Therapeutics and chair of the board of directors at BIO.

8. How Can Leaders Keep Employees Motivated And Focused On Long-Term Objectives In The Context Of Difficult Market Conditions And Short-Term Belt Tightening? 11/1/2022

   See the answer from Paula Ragan, cofounder, president, and CEO of X4 Pharmaceuticals.

9. How Can Novel Data Registries Inform The Development Of New Medicines, Or Improve Patient Care? 10/3/2022

   See the answer from Lisa Conte, founder, president, and CEO of Jaguar Health.

10. Your New Book Is Pharma And Profits: Balancing Innovation, Medicine And Drug Pricing. What Is Most Often Overlooked In Political Discussions About Drug Prices? 10/3/2022

    See the answer from John Lamattina, a senior partner at PureTech Health.